RadNet, Inc. (NASDAQ:RDNT) Stake Lifted by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans increased its stake in RadNet, Inc. (NASDAQ:RDNT) by 1.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,758 shares of the medical research company’s stock after acquiring an additional 552 shares during the period. Thrivent Financial for Lutherans owned approximately 0.07% of RadNet worth $1,205,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of RDNT. Nisa Investment Advisors LLC bought a new position in shares of RadNet in the second quarter valued at approximately $25,000. Advisor Group Holdings Inc. bought a new position in shares of RadNet in the second quarter valued at approximately $33,000. PNC Financial Services Group Inc. boosted its holdings in shares of RadNet by 51.3% in the second quarter. PNC Financial Services Group Inc. now owns 1,814 shares of the medical research company’s stock valued at $62,000 after acquiring an additional 615 shares in the last quarter. O Shaughnessy Asset Management LLC boosted its holdings in shares of RadNet by 1,026.2% in the second quarter. O Shaughnessy Asset Management LLC now owns 2,320 shares of the medical research company’s stock valued at $78,000 after acquiring an additional 2,114 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of RadNet by 26.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,663 shares of the medical research company’s stock valued at $157,000 after acquiring an additional 972 shares in the last quarter. Institutional investors and hedge funds own 67.44% of the company’s stock.

RDNT has been the subject of several recent analyst reports. Zacks Investment Research cut shares of RadNet from a “buy” rating to a “hold” rating in a report on Tuesday, November 16th. Barclays initiated coverage on shares of RadNet in a report on Thursday, August 12th. They set an “overweight” rating and a $39.00 target price for the company. Raymond James cut shares of RadNet from an “outperform” rating to a “market perform” rating in a report on Thursday, August 12th. Finally, TheStreet upgraded shares of RadNet from a “c” rating to a “b-” rating in a report on Wednesday, November 17th. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $35.00.

In other RadNet news, SVP Ruth Louisa Villigerwilson sold 3,246 shares of the stock in a transaction that occurred on Thursday, September 2nd. The shares were sold at an average price of $31.47, for a total value of $102,151.62. Following the completion of the sale, the senior vice president now owns 16,914 shares in the company, valued at approximately $532,283.58. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Norman R. Hames sold 35,000 shares of the stock in a transaction that occurred on Friday, October 1st. The stock was sold at an average price of $28.57, for a total transaction of $999,950.00. The disclosure for this sale can be found here. Company insiders own 5.80% of the company’s stock.

RadNet stock opened at $28.48 on Thursday. The company has a 50 day moving average price of $29.82 and a 200 day moving average price of $30.79. RadNet, Inc. has a 52 week low of $17.27 and a 52 week high of $38.84. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.88 and a current ratio of 0.92. The firm has a market capitalization of $1.51 billion, a price-to-earnings ratio of 44.50 and a beta of 1.64.

RadNet (NASDAQ:RDNT) last posted its quarterly earnings data on Monday, November 8th. The medical research company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.03. RadNet had a net margin of 2.67% and a return on equity of 12.87%. The firm had revenue of $332.70 million during the quarter, compared to analyst estimates of $341.26 million. During the same quarter last year, the business posted $0.15 EPS. The company’s revenue was up 14.0% on a year-over-year basis. Equities analysts forecast that RadNet, Inc. will post 0.78 earnings per share for the current fiscal year.

RadNet Company Profile

RadNet, Inc provides freestanding, fixed-site outpatient diagnostic imaging services in the United States. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and reduce unnecessary invasive procedures. The firm offers magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures.

See Also: What is a Fibonacci Channel?

Institutional Ownership by Quarter for RadNet (NASDAQ:RDNT)

Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.